Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Weiguo Zhang, Hongying Zhang, Andrea Local, William G. Rice, Charlie J. Ly, Guopan Yu, Stephen B. Howell and Michael Andreeff | ||||||||||||
Title | CG?806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3 | ||||||||||||
|
|||||||||||||
URL | http://clincancerres.aacrjournals.org/content/23/24_Supplement/25 | ||||||||||||
Abstract Text | Clin Cancer Res 2017;23(24_Suppl):Abstract nr 25 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|